4//SEC Filing
Valantine Hannah 4
Accession 0000950170-25-036420
CIK 0001743881other
Filed
Mar 9, 8:00 PM ET
Accepted
Mar 10, 4:43 PM ET
Size
9.5 KB
Accession
0000950170-25-036420
Insider Transaction Report
Form 4
Valantine Hannah
Director
Transactions
- Exercise/Conversion
Common Stock
2025-03-06$16.75/sh+12,875$215,656→ 14,639 total - Sale
Common Stock
2025-03-06$32.58/sh−12,875$419,500→ 1,764 total - Exercise/Conversion
Stock Option (right to buy)
2025-03-06−12,875→ 38,626 totalExercise: $16.75Exp: 2033-06-21→ Common Stock (12,875 underlying)
Holdings
- 3,433(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024.
- [F2]Represents the weighted average sale price of the shares sold from $32.17 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]The stock option vests in three annual installments starting on June 21, 2024 and ending on June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001855608
Filing Metadata
- Form type
- 4
- Filed
- Mar 9, 8:00 PM ET
- Accepted
- Mar 10, 4:43 PM ET
- Size
- 9.5 KB